Medical cannabis oil
Scanleaf's medicines comply with section 9(1) of the Danish Act on a Medicinal Cannabis Pilot Programme and on a scheme for cultivation, production, etc. of medicinal cannabis. This means that patients and prescribers can rest assured that our labelling is accurate (tested multiple times to ensure patients receive the correct amount of cannabinoids as prescribed) and that all our products are free from contaminants such as pesticides, moulds, bacteria, heavy metals, etc.
THC 25 Scanleaf
30 mL
Application:
Oral liquid
1 mL contain:
33-41 mg extract (as soft extract) of Cannabis sativa L., flos (cannabis flower), corresponding to 25 mg dronabinol (THC) and maximum 1 mg cannabidiol (CBD).
Cultivar: White Widow (Denmark)
Oral dosing syringes of 1,0 mL with a graduation of 0,01 mL in outer carton.
Product sheet and patient information sheet
Any cannabis intermediate product and related cannabis primary product that are to be comprised by the medicinal cannabis pilot programme must be admitted to a list published by the Danish Medicines Agency. The list allows anyone to see which cannabis intermediate products are comprised by the pilot programme, and hence which products may be lawfully prescribed by doctors and lawfully dispensed by pharmacies in Denmark.
Below you can find the product sheet and patient information sheet (description of the preparation method) for THC 25 Scanleaf:
Cannabinoid and terpene profile
Disclaimer: Scanleaf ApS disclaims all responsibility for the correctness of the data in the graphs below. The material is not part of Scanleafs official information and documentation about its products. Readers are cautioned not to place undue reliance on the material. Use of the material is at the readers own risk and Scanleaf disclaims all and any liability in connection with its use.
Scanleaf is currently in the process of getting more products approved by the Danish Medicines Agency. The products will be listed on this website as soon as they can be prescribed as medicine in Denmark.